ID

31663

Description

Combination Iodine 125 Seed Implants and LHRH Agonists for Locally Advanced (Stage T3) Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01813097

Link

https://clinicaltrials.gov/show/NCT01813097

Keywords

Versions (1)
  1. 9/18/18 9/18/18 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

September 18, 2018

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Prostate Cancer NCT01813097

English

Eligibility Prostate Cancer NCT01813097

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. provision of written informed consent
Description

Informed Consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
2. t2c-t3b n0 m0 (biopsy、 bone scan、 ct、 mri)
Description

TNM clinical staging Biopsy | TNM clinical staging Bone scan | TNM clinical staging CT | TNM clinical staging MRI

Data type

boolean

Alias
UMLS CUI [1,1]
C3258246
UMLS CUI [1,2]
C0005558
UMLS CUI [2,1]
C3258246
UMLS CUI [2,2]
C0203668
UMLS CUI [3,1]
C3258246
UMLS CUI [3,2]
C0040405
UMLS CUI [4,1]
C3258246
UMLS CUI [4,2]
C0024485
3. no metastasis (bone scan、 ct、 mri)
Description

Neoplasm Metastasis Absent Bone scan | Neoplasm Metastasis Absent CT | Neoplasm Metastasis Absent MRI

Data type

boolean

Alias
UMLS CUI [1,1]
C0027627
UMLS CUI [1,2]
C0332197
UMLS CUI [1,3]
C0203668
UMLS CUI [2,1]
C0027627
UMLS CUI [2,2]
C0332197
UMLS CUI [2,3]
C0040405
UMLS CUI [3,1]
C0027627
UMLS CUI [3,2]
C0332197
UMLS CUI [3,3]
C0024485
4. psa level>10ng/ml
Description

Prostate specific antigen measurement

Data type

boolean

Alias
UMLS CUI [1]
C0201544
5. histological or cytological confirmation of prostate cancer
Description

Prostate carcinoma

Data type

boolean

Alias
UMLS CUI [1]
C0600139
6. able to understand and comply with the requirements of the study
Description

Comprehension Study Protocol | Protocol Compliance

Data type

boolean

Alias
UMLS CUI [1,1]
C0162340
UMLS CUI [1,2]
C2348563
UMLS CUI [2]
C0525058
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. having been treated with external radiation therapy or chemistry therapy.
Description

External beam radiotherapy | Chemotherapy

Data type

boolean

Alias
UMLS CUI [1]
C0419095
UMLS CUI [2]
C0392920
2. clinical relevant disease and/or abnormalities (past or present), eg, significant cardiovascular, renal or liver disease, malignancy, gastro-intestinal disorders, or other conditions which could affect the absorption/elimination of drugs.
Description

Disease Clinical Relevant | Abnormality Clinical Relevant | Cardiovascular Diseases | Kidney Diseases | Liver diseases | Malignant Neoplasms | Gastrointestinal Diseases | Other medical condition Affecting Drug absorption | Other medical condition Affecting Drug elimination

Data type

boolean

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C0205210
UMLS CUI [1,3]
C2347946
UMLS CUI [2,1]
C1704258
UMLS CUI [2,2]
C0205210
UMLS CUI [2,3]
C2347946
UMLS CUI [3]
C0007222
UMLS CUI [4]
C0022658
UMLS CUI [5]
C0023895
UMLS CUI [6]
C0006826
UMLS CUI [7]
C0017178
UMLS CUI [8,1]
C3843040
UMLS CUI [8,2]
C0392760
UMLS CUI [8,3]
C0678745
UMLS CUI [9,1]
C3843040
UMLS CUI [9,2]
C0392760
UMLS CUI [9,3]
C0683141
3. alanine amino transferase (alt) or aspartate amino transferase (ast) greater than 2 times the upper limit of normal (uln) at screening findings that make it undesirable for the patient to participate in the study in the opinion of the investigator(s)
Description

Alanine aminotransferase increased | Aspartate aminotransferase increased | Study Subject Participation Status Unfavorable

Data type

boolean

Alias
UMLS CUI [1]
C0151905
UMLS CUI [2]
C0151904
UMLS CUI [3,1]
C2348568
UMLS CUI [3,2]
C3640815
4. in the opinion of the investigator(s), any evidence of severe or uncontrolled systemic disease (eg, currently unstable or unresolved respiratory, cardiac, hepatic, or renal disease).
Description

Systemic disease Severe | Systemic disease Uncontrolled | Respiration Disorder Unstable | Heart Disease Unstable | Liver disease Unstable | Kidney Disease Unstable | Respiration Disorder Without Resolution | Heart Disease Without Resolution | Liver disease Without Resolution | Kidney Disease Without Resolution

Data type

boolean

Alias
UMLS CUI [1,1]
C0442893
UMLS CUI [1,2]
C0205082
UMLS CUI [2,1]
C0442893
UMLS CUI [2,2]
C0205318
UMLS CUI [3,1]
C0035204
UMLS CUI [3,2]
C0443343
UMLS CUI [4,1]
C0018799
UMLS CUI [4,2]
C0443343
UMLS CUI [5,1]
C0023895
UMLS CUI [5,2]
C0443343
UMLS CUI [6,1]
C0022658
UMLS CUI [6,2]
C0443343
UMLS CUI [7,1]
C0035204
UMLS CUI [7,2]
C0332288
UMLS CUI [7,3]
C1514893
UMLS CUI [8,1]
C0018799
UMLS CUI [8,2]
C0332288
UMLS CUI [8,3]
C1514893
UMLS CUI [9,1]
C0023895
UMLS CUI [9,2]
C0332288
UMLS CUI [9,3]
C1514893
UMLS CUI [10,1]
C0022658
UMLS CUI [10,2]
C0332288
UMLS CUI [10,3]
C1514893
5. contra-indications (eg, known or suspected allergy) to gnrh antagonists or excipients(non-active ingredients of investigational product).
Description

Medical contraindication GnRH antagonist | Hypersensitivity GnRH antagonist | Hypersensitivity Suspected GnRH antagonist | Medical contraindication GnRH Excipient | Hypersensitivity GnRH Excipient | Hypersensitivity Suspected GnRH Excipient

Data type

boolean

Alias
UMLS CUI [1,1]
C1301624
UMLS CUI [1,2]
C1268855
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C1268855
UMLS CUI [3,1]
C0020517
UMLS CUI [3,2]
C0750491
UMLS CUI [3,3]
C1268855
UMLS CUI [4,1]
C1301624
UMLS CUI [4,2]
C0023610
UMLS CUI [4,3]
C0015237
UMLS CUI [5,1]
C0020517
UMLS CUI [5,2]
C0023610
UMLS CUI [5,3]
C0015237
UMLS CUI [6,1]
C0020517
UMLS CUI [6,2]
C0750491
UMLS CUI [6,3]
C0023610
UMLS CUI [6,4]
C0015237
6. treatment with a non-approved or investigational drug within 30 days before study entry.
Description

Drugs, Non-Prescription | Investigational New Drugs

Data type

boolean

Alias
UMLS CUI [1]
C0013231
UMLS CUI [2]
C0013230
7. bibulosity or drug abuse.
Description

Substance Use Disorders

Data type

boolean

Alias
UMLS CUI [1]
C0038586
Back to the top of the page

Similar models

Eligibility Prostate Cancer NCT01813097

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Informed Consent
Item
1. provision of written informed consent
boolean
C0021430 (UMLS CUI [1])
TNM clinical staging Biopsy | TNM clinical staging Bone scan | TNM clinical staging CT | TNM clinical staging MRI
Item
2. t2c-t3b n0 m0 (biopsy、 bone scan、 ct、 mri)
boolean
C3258246 (UMLS CUI [1,1])
C0005558 (UMLS CUI [1,2])
C3258246 (UMLS CUI [2,1])
C0203668 (UMLS CUI [2,2])
C3258246 (UMLS CUI [3,1])
C0040405 (UMLS CUI [3,2])
C3258246 (UMLS CUI [4,1])
C0024485 (UMLS CUI [4,2])
Neoplasm Metastasis Absent Bone scan | Neoplasm Metastasis Absent CT | Neoplasm Metastasis Absent MRI
Item
3. no metastasis (bone scan、 ct、 mri)
boolean
C0027627 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C0203668 (UMLS CUI [1,3])
C0027627 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C0040405 (UMLS CUI [2,3])
C0027627 (UMLS CUI [3,1])
C0332197 (UMLS CUI [3,2])
C0024485 (UMLS CUI [3,3])
Prostate specific antigen measurement
Item
4. psa level>10ng/ml
boolean
C0201544 (UMLS CUI [1])
Prostate carcinoma
Item
5. histological or cytological confirmation of prostate cancer
boolean
C0600139 (UMLS CUI [1])
Comprehension Study Protocol | Protocol Compliance
Item
6. able to understand and comply with the requirements of the study
boolean
C0162340 (UMLS CUI [1,1])
C2348563 (UMLS CUI [1,2])
C0525058 (UMLS CUI [2])
Item Group
C0680251 (UMLS CUI)
External beam radiotherapy | Chemotherapy
Item
1. having been treated with external radiation therapy or chemistry therapy.
boolean
C0419095 (UMLS CUI [1])
C0392920 (UMLS CUI [2])
Disease Clinical Relevant | Abnormality Clinical Relevant | Cardiovascular Diseases | Kidney Diseases | Liver diseases | Malignant Neoplasms | Gastrointestinal Diseases | Other medical condition Affecting Drug absorption | Other medical condition Affecting Drug elimination
Item
2. clinical relevant disease and/or abnormalities (past or present), eg, significant cardiovascular, renal or liver disease, malignancy, gastro-intestinal disorders, or other conditions which could affect the absorption/elimination of drugs.
boolean
C0012634 (UMLS CUI [1,1])
C0205210 (UMLS CUI [1,2])
C2347946 (UMLS CUI [1,3])
C1704258 (UMLS CUI [2,1])
C0205210 (UMLS CUI [2,2])
C2347946 (UMLS CUI [2,3])
C0007222 (UMLS CUI [3])
C0022658 (UMLS CUI [4])
C0023895 (UMLS CUI [5])
C0006826 (UMLS CUI [6])
C0017178 (UMLS CUI [7])
C3843040 (UMLS CUI [8,1])
C0392760 (UMLS CUI [8,2])
C0678745 (UMLS CUI [8,3])
C3843040 (UMLS CUI [9,1])
C0392760 (UMLS CUI [9,2])
C0683141 (UMLS CUI [9,3])
Alanine aminotransferase increased | Aspartate aminotransferase increased | Study Subject Participation Status Unfavorable
Item
3. alanine amino transferase (alt) or aspartate amino transferase (ast) greater than 2 times the upper limit of normal (uln) at screening findings that make it undesirable for the patient to participate in the study in the opinion of the investigator(s)
boolean
C0151905 (UMLS CUI [1])
C0151904 (UMLS CUI [2])
C2348568 (UMLS CUI [3,1])
C3640815 (UMLS CUI [3,2])
Systemic disease Severe | Systemic disease Uncontrolled | Respiration Disorder Unstable | Heart Disease Unstable | Liver disease Unstable | Kidney Disease Unstable | Respiration Disorder Without Resolution | Heart Disease Without Resolution | Liver disease Without Resolution | Kidney Disease Without Resolution
Item
4. in the opinion of the investigator(s), any evidence of severe or uncontrolled systemic disease (eg, currently unstable or unresolved respiratory, cardiac, hepatic, or renal disease).
boolean
C0442893 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C0442893 (UMLS CUI [2,1])
C0205318 (UMLS CUI [2,2])
C0035204 (UMLS CUI [3,1])
C0443343 (UMLS CUI [3,2])
C0018799 (UMLS CUI [4,1])
C0443343 (UMLS CUI [4,2])
C0023895 (UMLS CUI [5,1])
C0443343 (UMLS CUI [5,2])
C0022658 (UMLS CUI [6,1])
C0443343 (UMLS CUI [6,2])
C0035204 (UMLS CUI [7,1])
C0332288 (UMLS CUI [7,2])
C1514893 (UMLS CUI [7,3])
C0018799 (UMLS CUI [8,1])
C0332288 (UMLS CUI [8,2])
C1514893 (UMLS CUI [8,3])
C0023895 (UMLS CUI [9,1])
C0332288 (UMLS CUI [9,2])
C1514893 (UMLS CUI [9,3])
C0022658 (UMLS CUI [10,1])
C0332288 (UMLS CUI [10,2])
C1514893 (UMLS CUI [10,3])
Medical contraindication GnRH antagonist | Hypersensitivity GnRH antagonist | Hypersensitivity Suspected GnRH antagonist | Medical contraindication GnRH Excipient | Hypersensitivity GnRH Excipient | Hypersensitivity Suspected GnRH Excipient
Item
5. contra-indications (eg, known or suspected allergy) to gnrh antagonists or excipients(non-active ingredients of investigational product).
boolean
C1301624 (UMLS CUI [1,1])
C1268855 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C1268855 (UMLS CUI [2,2])
C0020517 (UMLS CUI [3,1])
C0750491 (UMLS CUI [3,2])
C1268855 (UMLS CUI [3,3])
C1301624 (UMLS CUI [4,1])
C0023610 (UMLS CUI [4,2])
C0015237 (UMLS CUI [4,3])
C0020517 (UMLS CUI [5,1])
C0023610 (UMLS CUI [5,2])
C0015237 (UMLS CUI [5,3])
C0020517 (UMLS CUI [6,1])
C0750491 (UMLS CUI [6,2])
C0023610 (UMLS CUI [6,3])
C0015237 (UMLS CUI [6,4])
Drugs, Non-Prescription | Investigational New Drugs
Item
6. treatment with a non-approved or investigational drug within 30 days before study entry.
boolean
C0013231 (UMLS CUI [1])
C0013230 (UMLS CUI [2])
Substance Use Disorders
Item
7. bibulosity or drug abuse.
boolean
C0038586 (UMLS CUI [1])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial